Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study. 2022 Feb 23;13:773999. doi: 10.3389/fneur.2022.773999. eCollection 2022. PMID: 35280262.